Polar Capital Holdings PLC Revance Therapeutics, Inc. Transaction History

Polar Capital Holdings PLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.34 - $4.73 $743,371 - $1.5 Million	-317,680 Reduced 8.18%	3,567,139 $9.17 Million
Q1 2024 May 15, 2024	BUY	$4.65 - $9.31 $3.33 Million - $6.66 Million	715,580 Added 22.58%	3,884,819 $19.1 Million
Q4 2023 Feb 14, 2024	SELL	$5.81 - $11.2 $5.76 Million - $11.1 Million	-991,072 Reduced 23.82%	3,169,239 $27.9 Million
Q3 2023 Nov 14, 2023	SELL	$11.47 - $25.07 $86,380 - $188,802	-7,531 Reduced 0.18%	4,160,311 $47.7 Million
Q1 2023 Dec 13, 2023	BUY	$18.36 - $35.27 $138,269 - $265,618	7,531 Added 0.18%	4,167,842 $134 Million
Q1 2023 May 15, 2023	SELL	$18.36 - $35.27 $12.5 Million - $24 Million	-680,791 Reduced 14.04%	4,167,842 $134 Million
Q4 2022 Feb 14, 2023	BUY	$18.32 - $30.66 $7.09 Million - $11.9 Million	386,886 Added 8.67%	4,848,633 $89.5 Million
Q3 2022 Nov 14, 2022	BUY	$14.33 - $28.47 $19.3 Million - $38.3 Million	1,344,695 Added 43.14%	4,461,747 $120 Million
Q2 2022 Aug 15, 2022	BUY	$11.52 - $20.4 $7.61 Million - $13.5 Million	660,555 Added 26.89%	3,117,052 $43.1 Million
Q1 2022 May 16, 2022	BUY	$12.36 - $20.31 $2.43 Million - $4 Million	196,797 Added 8.71%	2,456,497 $47.9 Million
Q4 2021 Feb 14, 2022	BUY	$12.46 - $27.87 $6.44 Million - $14.4 Million	516,703 Added 29.64%	2,259,700 $36.9 Million
Q3 2021 Nov 15, 2021	BUY	$25.78 - $33.21 $15.2 Million - $19.5 Million	588,263 Added 50.94%	1,742,997 $48.6 Million
Q4 2020 Feb 16, 2021	BUY	$23.41 - $28.34 $27 Million - $32.7 Million	1,154,734 New	1,154,734 $32.7 Million

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Polar Capital Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Polar Capital Holdings PLC with notifications on news.